Zynerba Pharmaceuticals

(NASDAQ: ZYNE)
Health Care  |  Pharmaceuticals
0.86 0.0 0.0%
Stock Price | May 13, 2022, 4 p.m.
1 Follower
Bid: 0.86
Ask: 0.966
Prev. Close: 0.8557
52 Week Low: 0.8361
52 Week High: 6.07
PE Ratio:
Dividend Yield: %

Company Summary

Zynerba Pharmaceuticals Inc is a pharmaceutical company that is focused on developing and commercializing proprietary next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product pipeline consists Zygel which is a pharmaceutically-produced CBD, a non-euphoric cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.

Read more Read less

Recently Viewed Tickers

Premium An Urgent Market Update

66 Comments
1 year ago

Premium Cannabis Stocks Review - Pre-Market Edition 02/23/18

26 Comments
4 years ago

Premium Cannabis Stocks Review - AM Edition 02/21/18

23 Comments
4 years ago

Premium Cannabis Stocks Review - AM Edition 02/20/18

106 Comments
4 years ago

Premium Cannabis Stocks Review - Weekend Edition 02/20/18

113 Comments
4 years ago

Premium Cannabis Stocks Review - Pre-Market Edition 02/15/18

3 Comments
4 years ago

Premium Flying High Buy 02/14/18

50 Comments
4 years ago

Premium Cannabis Stocks Review - Weekend Edition 01/16/18

20 Comments
4 years ago

Premium Cannabis Stocks Review - AM Edition 01/10/18

31 Comments
4 years ago

Premium Cannabis Stocks Review - Pre-Market Edition 01/10/18

37 Comments
4 years ago